Ftse Mib
34.249,77
0,91%
DAX
18.161,01
1,32%
S&P 500
5.099,96
1,02%
NASDAQ Composite
15.927,90
2,03%
Bitcoin
63.832,46
0,66%

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Assistenza
Home Investire Azioni U.S.A. NASDAQ Regeneron Pharmaceuticals Inc (REGN) Regeneron Pharmaceuticals Inc (REGN) Notizie

Regeneron Pharmaceuticals Inc

REGN
883,20
-7,48 (-0,84%)
27 Apr 2024 - Chiuso
Dati in Delay di 15 minuti
Borsa: NASDAQ
Tipo: Azione
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
25/4/202413:00GLOBERegeneron and Mammoth Biosciences Collaborate to Pursue..
24/4/202416:05GLOBERegeneron to Showcase Progress in Advancing Novel..
22/4/202423:54GLOBERegeneron to Highlight Advances in Genetic Medicine Research..
16/4/202413:18IHMARKETNEWSEricsson Soars with 66% Net Profit Growth; Live Nation Under..
11/4/202413:24IHMARKETNEWSCostco Increases Dividend by 14%, Meta Introduces ‘Artemis’..
07/4/202422:00GLOBELinvoseltamab Pivotal Data Presented at AACR Reinforce High..
01/4/202422:05GLOBERegeneron to Report First Quarter 2024 Financial and..
25/3/202412:00GLOBERegeneron Provides Update on Biologics License Application..
13/3/202404:55PRNUSHigh School Seniors Win $1.8 Million at Regeneron Science..
13/3/202402:30GLOBEHigh School Seniors Win $1.8 Million at Regeneron Science..
11/3/202412:00GLOBEPraluent® (alirocumab) Injection Receives FDA Approval to..
08/3/202413:00GLOBEEYLEA® HD (aflibercept) Injection 8 mg Pivotal Data in Wet..
05/3/202422:01EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/3/202422:01EDGAR2Form 4 - Statement of changes in beneficial ownership of..
01/3/202422:14EDGAR2Form 144 - Report of proposed sale of securities
28/2/202422:04EDGAR2Form 4 - Statement of changes in beneficial ownership of..
28/2/202422:04EDGAR2Form 4 - Statement of changes in beneficial ownership of..
28/2/202422:04EDGAR2Form 4 - Statement of changes in beneficial ownership of..
26/2/202422:34EDGAR2Form 144 - Report of proposed sale of securities
26/2/202422:07EDGAR2Form 4 - Statement of changes in beneficial ownership of..
26/2/202422:07EDGAR2Form 4 - Statement of changes in beneficial ownership of..
26/2/202422:07EDGAR2Form 144 - Report of proposed sale of securities
26/2/202422:07EDGAR2Form 4 - Statement of changes in beneficial ownership of..
26/2/202421:25EDGAR2Form 144 - Report of proposed sale of securities
23/2/202422:04EDGAR2Form 144 - Report of proposed sale of securities
23/2/202407:00GLOBEDupixent® (dupilumab) sBLA Accepted for FDA Priority Review..
22/2/202423:10EDGAR2Form 144 - Report of proposed sale of securities
22/2/202422:06EDGAR2Form 144 - Report of proposed sale of securities
21/2/202413:00GLOBELinvoseltamab BLA for Treatment of Relapsed/Refractory..
20/2/202422:03EDGAR2Form 4 - Statement of changes in beneficial ownership of..
16/2/202422:15EDGAR2Form 4 - Statement of changes in beneficial ownership of..
16/2/202406:59GLOBEJapan First in the World to Approve Dupixent® (dupilumab)..
14/2/202423:08EDGAR2Form 144 - Report of proposed sale of securities
12/2/202422:02EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12/2/202422:02EDGAR2Form 4 - Statement of changes in beneficial ownership of..
10/2/202400:19EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
09/2/202422:12EDGAR2Form 4 - Statement of changes in beneficial ownership of..
09/2/202422:04EDGAR2Form 144 - Report of proposed sale of securities
09/2/202418:22EDGAR2Form 144 - Report of proposed sale of securities
08/2/202422:56EDGAR2Form 144 - Report of proposed sale of securities
08/2/202422:26EDGAR2Form 144 - Report of proposed sale of securities
08/2/202422:02EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08/2/202422:01EDGAR2Form 3 - Initial statement of beneficial ownership of..
07/2/202423:59EDGAR2Form 144 - Report of proposed sale of securities
07/2/202423:07EDGAR2Form 144 - Report of proposed sale of securities
07/2/202422:35EDGAR2Form 144 - Report of proposed sale of securities
06/2/202422:08EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/2/202422:08EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/2/202422:08EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/2/202422:05GLOBERegeneron Announces Investor Conference Presentations
Apertura: 881,72 Min: 875,225 Max: 887,4794
Chiusura: 890,68

La tua Cronologia

NASDAQ
REGN
Regeneron Pharmaceuticals
Delayed Upgrade Clock

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' CLICCA QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network